Article

Utilizing proteomics and phosphoproteomics to predict <i>ex vivo</i> drug sensitivity across genetically diverse AML patients

2021-06-06

Abstract excerpt

Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populations of leukemia. This genetic heterogeneity is difficult to treat using conventional therapies that are generally based on the detection of a single driving mutation....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b00b9e4d-70ae-595a-a568-577cd62913ce
DOI: 10.1101/2021.06.04.447154

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Utilizing proteomics and phosphoproteomics to predict <i>ex vivo</i> drug sensitivity across genetically diverse AML patientsDOI 10.1101/2021.06.04.447154Read

Proteomics and Phosphoprotoemic Measurements Enhance Ability to Predict Ex Vivo Drug Response in AMLSemantic proximity Read

Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AMLSemantic proximity Read

Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia.Semantic proximity Read

Proteomic Characterization of Acute Myeloid Leukemia for Precision MedicineSemantic proximity Read

Mutation Patterns Predict Drug Sensitivity in Acute Myeloid LeukemiaSemantic proximity Read

What do functional genomics tell us about pathogenesis of AML?Semantic proximity Read

A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia.Semantic proximity Read

Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cellsSemantic proximity Read

Proteomic and phosphoproteomic landscapes of acute myeloid leukemia.Semantic proximity Read

Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspectiveSemantic proximity Read

A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug PerturbationsSemantic proximity Read

Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside agingSemantic proximity Read